AR082223A1 - Formulacion liquida de un conjugado de hormona del crecimiento humano de efecto prolongado, metodo - Google Patents

Formulacion liquida de un conjugado de hormona del crecimiento humano de efecto prolongado, metodo

Info

Publication number
AR082223A1
AR082223A1 ARP110102545A ARP110102545A AR082223A1 AR 082223 A1 AR082223 A1 AR 082223A1 AR P110102545 A ARP110102545 A AR P110102545A AR P110102545 A ARP110102545 A AR P110102545A AR 082223 A1 AR082223 A1 AR 082223A1
Authority
AR
Argentina
Prior art keywords
conjugate
hgh
human
region
human growth
Prior art date
Application number
ARP110102545A
Other languages
English (en)
Inventor
Jae Min Lee
Sung Hee Hong
Sung Min Bae
Byung Sun Lee
Dae Seong Im
Se Chang Kwon
Original Assignee
Hanmi Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co Ltd filed Critical Hanmi Holdings Co Ltd
Publication of AR082223A1 publication Critical patent/AR082223A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulación líquida de un conjugado de hormona del crecimiento humano (hGH) de efecto prolongado, libre de albúmina, que puede garantizar la estabilidad del conjugado de hGH durante su almacenamiento por períodos prolongados. El conjugado de hormona del crecimiento humano incluye una hGH unida a la región Fc de una inmunoglobulina, y tiene una mayor estabilidad in vivo que la forma nativa. La formulación líquida de conjugado de hGH que incluye una solución amortiguadora de pH 5.0 ~ 6.0, un alcohol de azúcar, una sal y un tensioactivo no iónico, y está libre de suero humano y de otros factores riesgosos que potencialmente pueden contaminarse con virus. La formulación provee una estabilidad excelente durante el almacenamiento, y brinda un conjugado de hGH de efecto prolongado compuesto por un polipeptido de hGh y la región Fc de una inmunoglobulina que tiene más peso molecular y mayor durabilidad en vivo que la forma nativa.Reivindicación 18: La formulación líquida de conjugado de la hormona del crecimiento humano de efecto prolongado de la reivindicación 17, en donde la región Fc de una inmunoglobulina es una región Fc de la IgG4 humana aglucosilada.
ARP110102545A 2010-07-14 2011-07-14 Formulacion liquida de un conjugado de hormona del crecimiento humano de efecto prolongado, metodo AR082223A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020100067796A KR101337797B1 (ko) 2010-07-14 2010-07-14 지속형 인간 성장 호르몬 결합체 액상 제제

Publications (1)

Publication Number Publication Date
AR082223A1 true AR082223A1 (es) 2012-11-21

Family

ID=45469941

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110102545A AR082223A1 (es) 2010-07-14 2011-07-14 Formulacion liquida de un conjugado de hormona del crecimiento humano de efecto prolongado, metodo
ARP180100643A AR113034A2 (es) 2010-07-14 2018-03-20 Formulación líquida de un conjugado de la hormona del crecimiento humano de efecto prolongado

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP180100643A AR113034A2 (es) 2010-07-14 2018-03-20 Formulación líquida de un conjugado de la hormona del crecimiento humano de efecto prolongado

Country Status (13)

Country Link
US (1) US9061072B2 (es)
EP (1) EP2593084B1 (es)
JP (1) JP5946448B2 (es)
KR (1) KR101337797B1 (es)
AR (2) AR082223A1 (es)
AU (1) AU2011277203B2 (es)
BR (1) BR112013000902A2 (es)
CA (1) CA2805228C (es)
ES (1) ES2673022T3 (es)
IL (1) IL224225B (es)
RU (1) RU2623026C2 (es)
TW (1) TWI459961B (es)
WO (1) WO2012008779A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2733544C2 (ru) 2011-06-17 2020-10-05 Ханми Сайенс Ко., Лтд. Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
US10064951B2 (en) * 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
EA039082B1 (ru) * 2012-11-06 2021-12-01 Ханми Фарм. Ко., Лтд. Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
CN105229035A (zh) * 2013-03-11 2016-01-06 诺和诺德保健股份有限公司 生长激素化合物
EP2970506A1 (en) 2013-03-11 2016-01-20 Novo Nordisk Health Care AG Growth hormone compounds
KR102276304B1 (ko) * 2013-09-27 2021-07-14 한미약품 주식회사 지속형 인간 성장 호르몬 제제
CN106488933A (zh) * 2014-03-31 2017-03-08 韩美药品株式会社 通过使用免疫球蛋白Fc片段连接改善蛋白质和肽的溶解度的方法
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
SG11201704706RA (en) * 2014-12-10 2017-07-28 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
US9375478B1 (en) * 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
WO2016193380A1 (en) 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
KR102661728B1 (ko) 2015-09-11 2024-04-26 다우 글로벌 테크놀로지스 엘엘씨 폴리알콕시 지방족 화합물
JP6883569B2 (ja) * 2015-09-11 2021-06-09 ダウ グローバル テクノロジーズ エルエルシー タンパク質及びポリアルコキシ脂肪族化合物を含む組成物
WO2017053677A1 (en) * 2015-09-24 2017-03-30 Biomarin Pharmaceutical Inc. Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
KR20170079409A (ko) * 2015-12-30 2017-07-10 한미약품 주식회사 지속형 인간 성장 호르몬 결합체의 신규 액상 제제
CN110505885A (zh) 2017-04-05 2019-11-26 诺和诺德股份有限公司 寡聚体延伸的胰岛素-Fc缀合物
US20220378882A1 (en) * 2019-10-30 2022-12-01 Jcr Pharmaceuticals Co., Ltd. Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
SE9201073D0 (sv) 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
JP4018133B2 (ja) * 1992-07-31 2007-12-05 ジェネンテック・インコーポレーテッド ヒト成長ホルモン水性製剤
US5519253A (en) * 1993-09-07 1996-05-21 Delco Electronics Corp. Coaxial switch module
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
JP4944324B2 (ja) * 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
US20060183197A1 (en) * 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
KR100537260B1 (ko) * 2003-09-03 2005-12-19 한미약품 주식회사 인간 성장 호르몬의 안정화된 액상 제제용 조성물
KR100775343B1 (ko) * 2003-11-13 2007-11-08 한미약품 주식회사 면역글로불린 Ｆｃ 영역을 캐리어로 포함하는 약제학적조성물
CA2551510C (en) * 2003-12-23 2013-07-30 Pharmacia Corporation Stable growth hormone liquid formulation
US8077437B2 (en) * 2004-11-08 2011-12-13 Enecsys Limited Integrated circuits and power supplies
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
KR100739728B1 (ko) * 2005-09-01 2007-07-13 삼성전자주식회사 화상형성시스템 및 화상 형성 방법
US8400775B2 (en) * 2007-07-06 2013-03-19 GM Global Technology Operations LLC Capacitor with direct DC connection to substrate
MY151184A (en) 2008-07-23 2014-04-30 Hanmi Science Co Ltd A polypeptide complex comprising non-peptidyl polymer having three functional ends
CN104398471A (zh) 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法

Also Published As

Publication number Publication date
AU2011277203A1 (en) 2013-02-28
CA2805228A1 (en) 2012-01-19
BR112013000902A2 (pt) 2020-08-25
RU2623026C2 (ru) 2017-06-21
CN103068366A (zh) 2013-04-24
JP5946448B2 (ja) 2016-07-06
WO2012008779A3 (en) 2012-05-24
ES2673022T3 (es) 2018-06-19
US9061072B2 (en) 2015-06-23
TWI459961B (zh) 2014-11-11
TW201215404A (en) 2012-04-16
AR113034A2 (es) 2020-01-22
EP2593084A4 (en) 2014-11-05
EP2593084B1 (en) 2018-03-14
KR20120007182A (ko) 2012-01-20
US20130115231A1 (en) 2013-05-09
EP2593084A2 (en) 2013-05-22
KR101337797B1 (ko) 2013-12-06
WO2012008779A2 (en) 2012-01-19
IL224225B (en) 2018-07-31
AU2011277203B2 (en) 2015-11-12
RU2013106276A (ru) 2014-08-20
JP2013531034A (ja) 2013-08-01
CA2805228C (en) 2019-05-07

Similar Documents

Publication Publication Date Title
AR082223A1 (es) Formulacion liquida de un conjugado de hormona del crecimiento humano de efecto prolongado, metodo
AR121939A2 (es) Composición líquida de un conjugado derivado de oxintomodulina de larga duración y procedimiento para prepararla
MX369479B (es) Formulación líquida de un cunjugado de péptido insulinotropico de acción prolongada.
AR091902A1 (es) Formulacion liquida de un conjugado de insulina de accion prolongada
AR095451A1 (es) Formulación de anticuerpos
EA201691297A1 (ru) Среда для культивирования клеток
PE20140795A1 (es) Composicion para tratar la diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada
RU2014140137A (ru) Лекарственный препарат антитела к бета-амилоиду
EA200970880A1 (ru) Стабильные композиции на основе антител
EA201690600A1 (ru) Метаболически оптимизированная клеточная культура
RU2015104489A (ru) Жидкая композиция длительно действующих инсулина и инсулинотропного пептида
BR112013026883A2 (pt) Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica
HRP20221139T1 (hr) Stabilizirane formulacije koje sadrže antitijela protiv interleukin-6 receptora (il-6r)
RU2017101667A (ru) Фармацевтические композиции
MX2013004595A (es) Formulaciones liquidas de un conjugado de alfa interferon de accion prolongada.
TW201129387A (en) Liquid formulation for long-acting G-CSF conjugate
PH12015501931B1 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
AR097840A1 (es) Una formulación de un conjugado de la hormona de crecimiento humana de la actividad prolongada, procedimiento, kit
AR089231A1 (es) Metodo de floculacion
PE20131034A1 (es) El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isomero posicional
AR090583A1 (es) Formulacion liquida de conjugados de la hormona de crecimiento humana de accion prolongada, altamente concentrada
AR088048A1 (es) Señuelos notch1 humanos
AR107276A1 (es) Una formulación líquida de conjugado de hormona del crecimiento humana de acción prolongada
AR094481A1 (es) Formulaciones de albu-bche (albúmina-butirilcolinesterasa), preparación y sus usos
Truskett et al. Concentrated dispersions of equilibrium protein nanoclusters that reversibly dissociate into active monomers

Legal Events

Date Code Title Description
FC Refusal